Probability of achieving bone mineral density treatment targets with abaloparatide and teriparatide
Study context
- Population
- Women with osteoporosis aged 49–86 yr in ACTIVE, with baseline TH or LS T-scores ≤−2.5ACTIVE enrolment
- Participants
- 2,463 women
- Comparison
- Abaloparatide or teriparatide (18 mo); abaloparatide/alendronate vs placebo/alendronate (3.5 yr)
- Primary endpoint
- Predicted probability of achieving a T-score >−2.5 at the TH or LS
- Follow-up
- 18 mo; 3.5 yr for sequential treatment
Methodological detailslogistic regression prediction model
- Logistic regression prediction model
Primary result
As reported in the abstract
Lowest baseline T-score with >50% predicted to achieve T-score >−2.5 · 18 mo
| Group | TH baseline T-score | LS baseline T-score |
|---|---|---|
| Abaloparatide | −2.7 | −3.3 |
| Teriparatide | −2.7 | −3.2 |
TH baseline T-score
Abaloparatide−2.7
Teriparatide−2.7
LS baseline T-score
Abaloparatide−3.3
Teriparatide−3.2
Further findings
| Outcome | Values |
|---|---|
| Lowest baseline T-score with >50% predicted to achieve T-score >−2.5, sequential treatment · 3.5 yr | Abaloparatide/alendronate TH baseline T-score ≥−2.9 · LS baseline T-score ≥−3.5 |
Baseline T-score ≤−2.5 in ACTIVE
- TH
- 23%
- LS
- 74%
Original publication
Probability of achieving bone mineral density treatment targets with abaloparatide and teriparatide. J Bone Miner Res. Published 11 April 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →